Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The outcome of 24 months of cabergoline treatment on prolactin (PRL) normalization, tumor shrinkage, restoration of pituitary function, and semen alterations was prospectively investigated in 41 men with macro- (age 17-70 yr) and 10 with microprolactinoma (age 18-53 yr). Fifty-one age-matched men served as controls for semen analysis. At study entry, of the 41 patients with macroprolactinoma, 17 (41.4%) had visual field defects, 14 (34.1%) had headache, eight (19.5%) had galactorrhea, 22 (53.6%) had hypopituitarism apart from hypogonadism, and 30 (73.2%) had low testosterone levels; of the 10 patients with microprolactinoma, none had visual field defects, galactorrhea, or hypopituitarism apart from hypogonadism, two had headache (20%), and five had low testosterone levels (50%; P = 0.3). After 24 months of therapy, 1) PRL levels normalized in 31 patients with macro- (75.6%) and in eight with microprolactinoma (80%; P = 0.9), and galactorrhea disappeared in all patients; 2) maximal tumor diameter reduced by 73.7 +/- 22.6% in macro- and 72.8 +/- 28.3% in microprolactinomas (P = 0.91), and 15 macro- (30%) and seven microprolactinomas (46.7%; P = 0.37) disappeared; 3) visual field defects disappeared in 15 (75%) patients with macroprolactinoma, and headache disappeared in 15 (83%) patients with macro- and in one with microprolactinoma (50%); 4) GH secretion recovered in 62.5% and ACTH secretion in 60% of patients; 5) testosterone levels normalized in 25 patients with macro- (60.9%) and six with microprolactinoma (60%) after 6 months, and 20 patients required testosterone or gonadotropin replacement (in 14 or six patients, respectively); and 6) sperm volume and count normalized in all patients who normalized testosterone levels, whereas motility normalized in more than 80%. Cabergoline therapy was well tolerated; only 4.5% of patients had side effects at high doses. These data demonstrate that cabergoline treatment is as effective and safe in men as in women with prolactinoma and can be successfully used as primary therapy even in men bearing large macroprolactinomas.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In case of a pituitary prolactinoma, treatment with dopamine agonists can be indicated and can result in normalization of testosterone levels and improvement of semen quality and libido [1,3,28,29,30].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [30]
In the citing paper
“Further research has reported the recovery of other hormonal axes following adenoma shrinkage (227)”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [227]
Citations
Cites
; (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.2.379 · Cited by 655
Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients
Verhelst, J., Abs, R., Maiter, D., van den Bruel, A., Vandeweghe, M., Velkeniers, B., Mockel, J., Lamberigts, G., Petrossians, P., Coremans, P., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5810 · Cited by 449
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
Colao, A., Di Sarno, A., Cappabianca, P., Di Somma, C., Pivonello, R., & Lombardi, G. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022657 · Cited by 336
Self-citationSex-Related Difference in the Growth of Prolactinomas: A Clinical and Proliferation Marker Study1
Delgrange, E., Trouillas, J., Maiter, D., Donckier, J., & Tourniaire, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4088 · Cited by 277
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
Colao, A. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.3.876 · Cited by 276
Self-citationColao, A., Sarno, A., Cappabianca, P., Briganti, F., Pivonello, R., Somma, C., Faggiano, A., Biondi, B., & Lombardi, G. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480325 · Cited by 267
Self-citationNew approach to the diagnosis of growth hormone deficiency in adults
Ghigo, E., Aimaretti, G., Gianotti, L., Bellone, J., Arvat, E., & Camanni, F. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1340352 · Cited by 257
Di Sarno, A., Landi, M. L., Cappabianca, P., Di Salle, F., Rossi, F. W., Pivonello, R., Di Somma, C., Faggiano, A., Lombardi, G., & Colao, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8054 · Cited by 247
Self-citationColao, A., Di Sarno, A., Landi, M. L., Scavuzzo, F., Cappabianca, P., Pivonello, R., Volpe, R., Di Salle, F., Cirillo, S., Annunziato, L., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6657 · Cited by 227
Self-citationTreatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline
Biller, B. M. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.6.2338 · Cited by 216
Colao, A., Di Somma, C., Pivonello, R., Loche, S., Aimaretti, G., Cerbone, G., Faggiano, A., Corneli, G., Ghigo, E., & Lombardi, G. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5742 · Cited by 190
Self-citationProlactinomas in Children and Adolescents. Clinical Presentation and Long-Term Follow-Up
Colao, A. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.8.2777 · Cited by 189
Self-citationLong-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage
Colao, A., Di Sarno, A., Landi, M. L., Cirillo, S., Sarnacchiaro, F., Facciolli, G., Pivonello, R., Cataldi, M., Merola, B., Annunziato, L., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.11.4368 · Cited by 163
Self-citationPrimary Medical Therapy of Micro- and Macroprolactinomas in Men
Pinzone, J. J. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.9.3053 · Cited by 161
Cannavò, S., Curtò, L., Squadrito, S., Almoto, B., Vieni, A., & Trimarchi, F. (1999) · Journal of Endocrinological Investigation · doi:10.1007/bf03343573 · Cited by 131
De Rosa, M., Colao, A., Di Sarno, A., Ferone, D., Landi, M., Zarrilli, S., Paesano, L., Merola, B., & Lombardi, G. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1380286 · Cited by 127
Self-citationBone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males
Di Somma, C. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.3.807 · Cited by 117
Self-citationMale Hyperprolactinemia: Effects on Fertility
Segal, S., Yaffe, H., Laufer, N., & Ben‐David, M. (1979) · Fertility and Sterility · doi:10.1016/s0015-0282(16)44359-1 · Cited by 106
Colao, A. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1277 · Cited by 102
Self-citationProlactinoma in 53 men: Clinical characteristics and modes of treatment (male prolactinoma)
Berezin, M., Shimon, I., & Hadani, M. (1995) · Journal of Endocrinological Investigation · doi:10.1007/bf03349742 · Cited by 94
De Rosa, M., Zarrilli, S., Vitale, G., Di Somma, C., Orio, F., Tauchmanova’, L., Lombardi, G., & Colao, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030852 · Cited by 87
Self-citationHYPERPROLACTINAEMIA IN MALES WITH AND WITHOUT PITUITARY MACROADENOMAS
Spark, R., OʼReilly, G. V., Wills, C., Ransil, B., & Bergland, R. M. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91094-7 · Cited by 68
Hyperprolactinaemia in males: A heterogeneous disorder
Walsh, J. P., & Pullan, P. T. (1997) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1997.tb02196.x · Cited by 54
Prolactinomas in Men: Clinical Characteristics and the Effect of Bromocriptine Treatment
Hulting, A. L., Muhr, C., Lundberg, P. O., & Werner, S. (1985) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1985.tb01642.x · Cited by 53
Prolactin secreting adenoma in 22 men.
Grisoli, F., Vincentelli, F., Jaquet, P., Guibout, M., Hassoun, J., & Farnarier, P. (1980) · PubMed · Cited by 46
Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males
Colao, A., De Rosa, M., Sarnacchiaro, F., Di Sarno, A., Landi, M. L., Iervolino, E., Zarrilli, S., Merola, B., & Lombardi, G. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1350548 · Cited by 45
Self-citationCabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases
Cappabianca, P., Lodrini, S., Felisati, G., Peca, C., Cozzi, R. C., Sarno, A. D., Cavallo, L. M., Giombini, S., & Colao, A. A. L. (2001) · Journal of Endocrinological Investigation · doi:10.1007/bf03343840 · Cited by 41
Self-citationRecovery of growth hormone secretion following cabergoline treatment of macroprolactinomas
George, L., Nicolau, N., Scanlon, M., & Davies, J. S. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01137.x · Cited by 28
Cited by
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1692 · Cited by 1,844
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Advances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
Self-citationPetersenn, S., Fleseriu, M., Casanueva, F. F., Giustina, A., Biermasz, N., Biller, B. M. K., Bronstein, M., Chanson, P., Fukuoka, H., Gadelha, M., et al. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00886-5 · Cited by 411
Schneider, H. J., Aimaretti, G., Kreitschmann-Andermahr, I., Stalla, G.-K., & Ghigo, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60673-4 · Cited by 336
Metadata
- Authors
- Colao, A., Vitale, G., Cappabianca, P., Briganti, F., Ciccarelli, A., De Rosa, M., Zarrilli, S., & Lombardi, G.
- Affiliations
- Federico II University Hospital (IT)
- Corresponding author
- Colao, Annamaria
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-04
- Volume
- 89
- Issue
- 4
- Pages
- 1704-1711
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2091047975
- Semantic Scholar
- 1e7fe5139d0e093e73f435b5c99704ece8f0a0ef
- Cited by
- 256
- References
- 28
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 14 · 2023: 15 · 2022: 13 · 2021: 13 · 2020: 7 · 2019: 13 · 2018: 8 · 2017: 11 · 2016: 15 · 2015: 8 · 2014: 10 · 2013: 16 · 2012: 11
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- cabergoline, prolactinoma, macroprolactinoma, microprolactinoma, prolactin normalization, tumor shrinkage, pituitary function recovery, hypogonadism, testosterone, semen quality, sperm count, sperm motility, visual field defects, headache, galactorrhea, hypopituitarism, dopamine agonists
- MeSH terms
- Cabergoline, Adolescent, Adult, Aged, Drug Administration Schedule, Ergolines, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Pituitary Gland, Pituitary Neoplasms, Prolactin, Semen, Prolactinoma, Treatment Outcome, Dopamine Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.